Maria Elena Toubes Navarro

Dr. Maria Elena Toubes Navarro

orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2014 in Respiratory Care
Verified
Journal Article
Open access
PDF file
LVLuis G. Valdés
Luis G. Valdés
EJEsther San José
Esther San José
LFLucía Ferreiro
Lucía Ferreiro
AGAntonio Golpe
Antonio Golpe
FGFrancisco Gude
Francisco Gude
Francisco-Javier Gonzalez-BarcalaFrancisco-Javier Gonzalez-Barcala
Francisco-Javier Gonzalez-Barcala
Introduction: The diagnosis of tuberculous pleural effusions (TBPE) has some limitations. Objective: To evaluate the efficacy of Interleukin-27 (IL-27) in the diagnosis of TBPE. Methods: A total of 431 pleural effusions were classified as tuberculous (n=70), neoplastic (n=146), parapneumonic (n=58), empyemas (n=28), miscellaneous (n=41), and transudates (n=88). IL-27, adenosine deaminase (ADA), ADA-2, interferon-gamma (IFNγ) and the ADA·IL-27 and ADA-2·IL-27 products were measured in all of the fluids. The diagnostic yield of IL-27 was evaluated using operating characteristics (ROC) analysis. Results: With a cut-off point of 0.55 ng/mL, IL-27 had a sensitivity of 91.4% and a specificity of 85.1%, which were significantly less than the rest of the parameters. The area under the ROC curve (0.963) was also significantly less than the rest of the markers, except for IFNγ. However, IL-27 improves the sensitivity of the ADA and ADA-2 through ADA·IL-27 and ADA-2·IL-27 products (100% for both). Conclusions: IL-27 is less efficient than ADA and ADA-2 in the diagnosis of TBPE. However, using the products of ADA·IL-27 and ADA-2·IL-27, helps to improve the diagnostic sensitivity of ADA and ADA-2, thus it could be useful in situations of high clinical suspicion and low levels of ADA. A value above the cut-off point of the latter is practically diagnostic of TBPE.

1 January 2022 in Respiratory Medicine
Verified
Journal Article
Closed access
JRJorge Ricoy
Jorge Ricoy
JSJuan Suárez-Antelo
Juan Suárez-Antelo
JAJosé Antúnez
José Antúnez
AAAnxo Martínez de Alegría
Anxo Martínez de Alegría
LFLucía Ferreiro
Lucía Ferreiro
LVLuis G. Valdés
Luis G. Valdés

2 October 2013 in Lung
Verified
Journal Article
Closed access
PDF file
LVLuis G. Valdés
Luis G. Valdés
ESEsther San-José
Esther San-José
LFLucía Ferreiro
Lucía Ferreiro
Francisco-Javier Gonzalez-BarcalaFrancisco-Javier Gonzalez-Barcala
Francisco-Javier Gonzalez-Barcala
AGAntonio Golpe
Antonio Golpe
FGFrancisco Gude
Francisco Gude

30 June 2022 in Heart & Lung
Verified
Journal Article
Closed access
AMANA CASAL MOURIÑO
ANA CASAL MOURIÑO
JSJuan Suárez-Antelo
Juan Suárez-Antelo
RSRoi Soto-Feijóo
Roi Soto-Feijóo
LFLucía Ferreiro
Lucía Ferreiro
NRNuria Rodríguez-Núñez
Nuria Rodríguez-Núñez
LVLuis G. Valdés
Luis G. Valdés

1 January 2024 in Respiratory Medicine
Verified
Journal Article
Closed access
JÁJosé M. Álvarez-Dobaño
José M. Álvarez-Dobaño
CGCarlota García
Carlota García
GAGerardo Atienza
Gerardo Atienza
MNMaria Elena Toubes Navarro
Maria Elena Toubes Navarro
NRNuria Rodríguez-Núñez
Nuria Rodríguez-Núñez
LVLuis G. Valdés
Luis G. Valdés

13 November 2024 in BMJ Open Respiratory Research
Verified
Journal Article
Open access
PDF file
NRNuria Rodríguez-Núñez
Nuria Rodríguez-Núñez
FGFrancisco Gude
Francisco Gude
LFLucía Ferreiro
Lucía Ferreiro
ELElisa Landín-Rey
Elisa Landín-Rey
MCMaría Carreiras-Cuiña
María Carreiras-Cuiña
LVLuis G. Valdés
Luis G. Valdés
Introduction: The characteristics and clinical relevance of pleural effusion (PLEF) in acute pulmonary embolism (APE) are not fully understood. Methods: A single-centre, retrospective study was performed of patients admitted with APE classified according to the subsequent development or not of PLEF. A model was built to predict PLEF and its impact on 30-day all-cause mortality was investigated. Results: A total of 1602 patients with APE were included (median age, 74 (61, 82) years; 674 men (42.1%); 382 (23.8%) with PLEF). PLEF was associated with a higher number of comorbidities (p=0.015); more peripheral APE (0.001); a higher frequency of pulmonary infarctions (p<0.001) and higher 30-day all-cause mortality (p=0.004) compared with those without PLEF. Bilateral PLEFs, as compared with unilateral, were associated with a higher number of comorbidities (p=0.009); more severe (simplified Pulmonary Embolism Severity Index ≥1; p<0.001) and higher 30-day all-cause mortality (p<0.001). On multivariate analysis, the presence of PLEF was associated with atrial fibrillation (OR 2.00; 95% CI 1.32 to 3.02), congestive heart failure (OR 3.00; 95% CI 1.81 to 5.00), pulmonary infarction (OR 3.19; 95% CI 2.38 to 4.29) and a Charlson index ≥3 (OR 1.59; 95% CI 1.03 to 2.45). The predictive model for PLEF had a moderate power of discrimination (area under the curve, AUC 0.76; 95% CI 0.73 to 0.79), whereas the predictive model for mortality showed a good predictive power (AUC 0.89; 95% CI 0.86 to 0.93). The presence of PLEF doubles the probability of death (OR 2.02; 95% CI 1.11 to 3.68). When PLEF is bilateral, the probability of death is four times higher, as compared with unilateral PLEF (OR 4.07; 95% CI 1.53 to 10.85; AUC 0.90; 95% CI 0.84 to 0.95). Conclusions: A significant number of APE patients develop PLEF. The model showed a good power of discrimination for the prediction of mortality. The probability of death from APE doubles in the presence of PLEF. Patients with APE and concomitant bilateral PLEF have a fourfold higher risk of mortality, as compared with patients with concomitant unilateral PLEF.